A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
Bausch & Lomb Incorporated
423 participants
Oct 24, 2025
INTERVENTIONAL
Conditions
Summary
A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks
Topical ocular drop of lifitegrast administered for 4 weeks
Topical ocular drop of perfluorohexyloctane administered for 4 weeks
Topical ocular drop with no active ingredients administered for 4 weeks
Topical ocular drop with no active ingredients administered for 4 weeks
Topical ocular drop with no active ingredients administered for 4 weeks
Locations(32)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07128628